- Home
- YALA vs GHRS Comparison
YALA vs GHRS Comparison
Compare YALA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | GHRS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United Arab Emirates | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YALA | GHRS |
|---|---|---|
| Price | $6.72 | $19.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 258.3K | 230.9K |
| Earning Date | 05-18-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.96 | $8.75 |
| 52 Week High | $9.29 | $24.66 |
Technical Indicators
Market Signals| Indicator | YALA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 62.81 |
| Support Level | $6.46 | $12.56 |
| Resistance Level | $7.29 | $24.66 |
| Average True Range (ATR) | 0.17 | 1.54 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 48.53 | 47.37 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.